Michael J. Donovan - Jul 6, 2023 Form 4 Insider Report for Renalytix plc (RNLX)

Role
Chief Medical Officer
Signature
/s/ Katie Kazem, Attorney-in-Fact
Stock symbol
RNLX
Transactions as of
Jul 6, 2023
Transactions value $
$0
Form type
4
Date filed
7/7/2023, 04:29 PM
Previous filing
Jul 3, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNLX Employee Stock Option (right to buy) Award $0 +85.7K $0.00 85.7K Jul 6, 2023 Ordinary Shares 85.7K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).
F2 One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service.